High-yield points
- Prognosis: median OS about 11 months. 2-year OS about 10%, and 5-year OS 2% .
- Diagnosis: a short history, the triad (CN VI/VII, ataxia, long tracts), and an expansile T2-bright pons engulfing the basilar artery .
- Ring enhancement and necrosis are bad signs.
- Age under 3 and a longer history are better signs .
- Biopsy is safe: 96% diagnostic, 0.6% permanent morbidity and 0.6% mortality.
- It is increasingly done for profiling and trials .
- Biology: H3 K27M or loss of H3K27me3 in essentially all cases.
- H3.1 (often with ACVR1) does better than H3.3 .
- Therapy:
- Radiation: 54 Gy, or hypofractionated with equal survival .
- Re-irradiation: helps at progression .
- Chemotherapy: fails; temozolomide 1-year EFS was 14% .
- ONC201: FDA-approved in 2025 for recurrent H3 K27M DMG .
- CAR T: an early signal .
Landmark papers
- International DIPG registry (Hoffman et al., J Clin Oncol 2018): 1,008 registry patients. 10% survived 2 years or more, and 5-year OS was 2% .
- ACNS0126 (Cohen et al., Neuro Oncol 2011): temozolomide added to radiation in 63 children. 1-year EFS was 14% vs the historical 21.9% .
DIPG is a diffusely infiltrating glioma of the pons and the deadliest solid tumor of childhood. Median survival is about 11 months, and only 2% are alive at 5 years . In WHO 2021 terms, almost all DIPGs are diffuse midline glioma, H3 K27-altered . "DIPG" remains the clinical and radiologic name.
Presentation and diagnosis
- Classic clinical picture :
- Short history: symptoms for 3 months or less.
- At least 2 of the neurologic triad:
- cranial nerve deficits (classically VI and VII);
- ataxia;
- long tract signs.
- Characteristic MRI.
- MRI:
- Features: a T2-hyperintense, expansile, infiltrative pontine mass that often engulfs the basilar artery.
- Diagnosis: typical imaging is enough to diagnose DIPG and start radiation without tissue.
- Long-term survivors (2 years or more, 10% of 1,008 registry patients) :
- Clinical features, more common in long-term survivors:
- presentation at age under 3 (11% vs. 3%) or over 10 (33% vs. 23%);
- longer symptom duration.
- Features more common in short-term survivors:
- cranial nerve palsy (83% vs. 73%);
- ring enhancement (38% vs. 23%);
- necrosis (42% vs. 26%);
- extrapontine extension.
- Survival prediction model (316 patients, median OS 10 months) :
- Favorable predictors:
- age 3 or younger;
- longer symptom duration;
- receiving chemotherapy.
- Unfavorable predictor: ring enhancement.
Biopsy: the shift
- Why biopsy now:
- Targets: biopsy finds actionable targets and makes trial enrollment possible.
- Diagnosis: it confirms H3 status and excludes mimics.
- Safety and yield:
- Meta-analysis of 735 stereotactic biopsies of pediatric brainstem tumors :
- Diagnostic success: 96.1%.
- Morbidity: 6.7% overall, and 0.6% permanent.
- Mortality: 0.6%.
- Trajectory (transfrontal vs. transcerebellar) made no difference.
- Prospective multicenter DIPG-BATS, 50 biopsies :
- Adequate tissue: 92%.
- Safety: no procedure-related deaths and one persistent hemiparesis.
- INFORM (21 biopsies) :
- Sequencing: DNA in all 21, and RNA in 16.
- Targets: potentially targetable alterations in 76%, including MET and NTRK1 fusions.
- Deficits: new or worse deficits in 9, mostly reversible. No deaths or severe bleeds.
- Practical points:
- Approaches: transfrontal or transcerebellar (via the middle cerebellar peduncle).
- Plan around trial requirements, since many trials require tissue.
- Indications: biopsy atypical cases (long history, focal or exophytic, enhancing) to exclude low-grade glioma and other mimics.
Molecular biology
- Nearly all DIPGs carry H3 K27M and/or loss of H3K27 trimethylation. In a biopsy series of 91, the exception was one tumor .
- H3.3 (H3F3A) vs. H3.1 (HIST1H3B/C) K27M :
- H3.3-mutant:
- responds less to radiotherapy and relapses earlier;
- metastasizes more at recurrence;
- phenotype: proneural, with PDGFRA activation.
- H3.1-mutant:
- better outcome;
- phenotype: mesenchymal and pro-angiogenic;
- associated with ACVR1 (H3.1 K27M with BCOR) .
- HIST1H3B mutation is enriched in long-term survivors (OR 1.28) .
Treatment
- Radiotherapy is the only proven therapy:
- Conventional: 54 Gy in 1.8-Gy fractions over 6 weeks .
- Hypofractionation (39 Gy/3 Gy or 44.8 Gy/2.8 Gy over 3–4 weeks) :
- Matched-cohort survival: same as conventional (median OS 9.0 vs. 9.4 months).
- Burden: less treatment.
- Steroids: 78% could temporarily stop them.
- Re-irradiation at progression (single institution, 118 children) :
- 6-month OS from recurrence: 66% vs. 22% without re-irradiation.
- Median survival: 6.9 vs. 2.7 months.
- Neurologic improvement: 61%.
- Longer survival when more than 1 year had passed since the first course (10.9 vs. 5.5 months).
- Chemotherapy:
- Temozolomide added to radiation (ACNS0126, 63 children) :
- 1-year EFS: 14% vs. the historical 21.9%.
- Median time to death: 9.6 months.
- No trial has changed survival: 26 trials in newly diagnosed DIPG over 5 years, including targeted agents, brought no clear improvement .
- No therapeutic progress in 50 years .
- ONC201 (dordaviprone):
- Two multisite studies of H3 K27M DMG, including DIPG :
- Median OS 21.7 months when started after radiation and before recurrence.
- 9.3 months when started after recurrence.
- FDA accelerated approval, August 2025: for H3 K27M DMG progressing after prior therapy, ages 1 year and older .
- CAR T cells (phase 1) :
- GD2-CAR T (IV, then intracerebroventricular) :
- Patients: 11 treated, 9 with DIPG and 2 with spinal DMG.
- Tumor reductions: 4 of 52–100%.
- Ongoing complete response: 1, lasting more than 30 months.
- Toxicity: all patients had tumor inflammation-associated neurotoxicity (TIAN).
- B7-H3 CAR T (repeated intracerebroventricular dosing, BrainChild-03) in 21 children with DIPG :
- Median survival: 19.8 months from diagnosis.
- Long-term survivors: 3 alive at 44–52 months.
- Neurosurgical relevance: these trials need ventricular access devices (Ommaya) and close watch for peritumoral swelling and hydrocephalus.
Neurosurgical roles
- Biopsy for diagnosis, molecular profiling and trial eligibility .
- Hydrocephalus: ETV or shunt.
- Access devices: placing ventricular access devices for intraventricular therapies .
- Neurotoxicity: managing tumor-inflammation neurotoxicity in cellular-therapy trials .
Related topics
- Diffuse Midline Glioma, H3 K27-Altered: the WHO 2021 entity, including thalamic and spinal DMG.
- Pediatric High-Grade Glioma: related pediatric high-grade gliomas and trial context.
- Endoscopic Third Ventriculostomy: treating associated hydrocephalus.
- Low-Grade Gliomas of the Brainstem in Children: focal brainstem gliomas, the main differential.
- Neurosurgical Delivery of Therapies for Inherited Metabolic and Genetic Brain Disorders: stereotactic, intraventricular and intrathecal delivery of genetic therapies.
References
- Hoffman LM, Veldhuijzen van Zanten SEM, Colditz N, et al. Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of diffuse intrinsic pontine glioma (DIPG): a collaborative report from the International and European Society for Pediatric Oncology DIPG Registries. J Clin Oncol 2018;36(19):1963–1972. doi:10.1200/JCO.2017.75.9308. PMID 29746225. verified
- Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23(8):1231–1251. doi:10.1093/neuonc/noab106. PMID 34185076. verified
- Castel D, Philippe C, Calmon R, et al. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol 2015;130(6):815–827. doi:10.1007/s00401-015-1478-0. PMID 26399631. verified
- Janssens GO, Jansen MH, Lauwers SJ, et al. Hypofractionation vs conventional radiation therapy for newly diagnosed diffuse intrinsic pontine glioma: a matched-cohort analysis. Int J Radiat Oncol Biol Phys 2013;85(2):315–320. doi:10.1016/j.ijrobp.2012.04.006. PMID 22682807. verified
- Jansen MH, Veldhuijzen van Zanten SE, Sanchez Aliaga E, et al. Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. Neuro Oncol 2015;17(1):160–166. doi:10.1093/neuonc/nou104. PMID 24903904. verified
- Hamisch C, Kickingereder P, Fischer M, et al. Update on the diagnostic value and safety of stereotactic biopsy for pediatric brainstem tumors: a systematic review and meta-analysis of 735 cases. J Neurosurg Pediatr 2017;20(3):261–268. doi:10.3171/2017.2.PEDS1665. PMID 28621573. verified
- Gupta N, Goumnerova LC, Manley P, et al. Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. Neuro Oncol 2018;20(11):1547–1555. doi:10.1093/neuonc/noy070. PMID 29741745. verified
- Pfaff E, El Damaty A, Balasubramanian GP, et al. Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience. Eur J Cancer 2019;114:27–35. doi:10.1016/j.ejca.2019.03.019. PMID 31022591. verified
- Mackay A, Burford A, Carvalho D, et al. Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell 2017;32(4):520–537.e5. doi:10.1016/j.ccell.2017.08.017. PMID 28966033. verified
- Shariff N, Moreno AS, Bennett J, et al. Re-irradiation for children with diffuse intrinsic pontine glioma and diffuse midline glioma. Radiother Oncol 2025;207:110865. doi:10.1016/j.radonc.2025.110865. PMID 40139463. verified
- Cohen KJ, Heideman RL, Zhou T, et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Neuro Oncol 2011;13(4):410–416. doi:10.1093/neuonc/noq205. PMID 21345842. verified
- Jansen MH, van Vuurden DG, Vandertop WP, Kaspers GJ. Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology. Cancer Treat Rev 2012;38(1):27–35. doi:10.1016/j.ctrv.2011.06.007. PMID 21764221. verified
- Venneti S, Kawakibi AR, Ji S, et al. Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways. Cancer Discov 2023;13(11):2370–2393. doi:10.1158/2159-8290.CD-23-0131. PMID 37584601. verified
- Blair HA. Dordaviprone: first approval. Drugs 2026;86(1):101–109. doi:10.1007/s40265-025-02252-3. PMID 41138047. verified
- Monje M, Mahdi J, Majzner R, et al. Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. Nature 2025;637(8046):708–715. doi:10.1038/s41586-024-08171-9. PMID 39537919. verified
- Vitanza NA, Ronsley R, Choe M, et al. Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial. Nat Med 2025;31(3):861–868. doi:10.1038/s41591-024-03451-3. PMID 39775044. verified
Verification (2026-11-13): each reference's authors, title, journal, volume, pages, DOI and PMID were checked on PubMed. Numbers were checked against the PubMed abstracts.
Caveats:
- The H3.1–ACVR1 association is attributed to reference 9's full analysis; its abstract states only H3.1 K27M–BCOR co-segregation.
- The following are standard teaching, not drawn from the cited abstracts:
- the CN VI/VII specifics;
- basilar artery engulfment;
- biopsy of atypical cases;
- the MCP trajectory.
- Re-irradiation and CAR T data are single-institution or phase 1.
- The figure is an original schematic.